Health Trials

SynKIR-310 for Relapsed/Refractory B-NHL

ConditionsB Cell LymphomaNHL, AdultMantle Cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaAggressive B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaFollicular LymphomaMarginal Zone LymphomaDLBCL - Diffuse Large B Cell LymphomaHGBL With MYC and BCL2 and/or BCL6 RearrangementsHigh-grade B-cell LymphomaDiffuse Large B Cell LymphomaLarge B-cell LymphomaT-Cell/Histiocyte Rich LymphomaNon-hodgkin Lymphoma,B CellPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Epstein-Barr Virus Positive DLBCL, NosFollicular Lymphoma Grade 3BDLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic InflammationHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedFollicular Lymphoma Grade 3Marginal Zone Splenic LymphomaDLBCLWaldenstrom MacroglobulinemiaWaldenstrom Macroglobulinaemia
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorVerismo Therapeutics

About this trial

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Eligibility criteria

Qualifiers

Adult 18 years of age and older.

Histologically confirmed diagnosis of B-NHL before enrollment.

Must have received prior CAR T or were unwilling/unable to receive prior CAR T.

Must have refractory or relapsed disease after receiving 2 prior lines of therapies.

Disqualifiers

Previously treated with any investigational agent within 30 days prior to screening.

Use of systemic immunosuppressive drugs within 4 weeks prior to study entry, or anticipated use of systemic immunosuppressive agents through end of study, with the exception of non-T cell targeting agents prior to leukapheresis

Known immunodeficiency disease , with the exception of hypoglobulinemia

History or presence of active or clinically relevant primary central nervous system (CNS) disorder, such as seizure, encephalopathy, cerebrovascular ischemia/hemorrhage, cerebellar disease, or any autoimmune disease with CNS involvement. For primary CNS disorders that have recovered or are in remission, participants without recurrence within 2 years of planned study enrollment may be included.

Trial design

Treatments tested in this trial

  • SynKIR-310

Treatment groups

36 Participants
are divided into 1 treatment group

Sponsors and collaborators

Verismo Therapeutics

Lead sponsor

Source ClinicalTrials.gov